Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Speeding Detection of Biologic Agents

By HospiMedica staff writers
Posted on 10 Mar 2006
Researchers are developing a faster technique to detect dangerous pathogens in the event of a biologic attack in order to speed the treatment of victims.

The grant, from Schott North America (Elmsford,, NY, USA), coupled with a U.S.1$ million grant from the U.S. More...
Department of Defense, will be used by the University of Scranton (PA, USA) to develop an automated, low-cost, highly sensitive tool to rapidly diagnose patients in the event of a bioterrorism attack.

The system involves a glass microarray platform divided into 96 sections. A sample containing DNA from biologic agents, such as bacteria or spores, is placed into each of the sections so that 96 tests can be run simultaneously to identify pathogens present in samples. This multiplexed technology allows each of the 96 tests to potentially diagnose up to 2,000 pathogens.

Current tests can identify only a single pathogen and take 14-72 hours or longer. This delay decreases the medical community's response time in treating patients who have been exposed to potentially deadly pathogens in the event of a biologic attack. The multiplexed microarray platform would significantly reduce the identification and confirmation time, and enable screening of biologic samples for multiple pathogens.

Stephen Krenitsky, vice president and site manager, Optics for Devices, Schott North America, observed, "By combining the University of Scranton's genomic, proteomic, and bioinformatics capabilities with Schott's advanced multiplexed bioarray platform, this research grant will create a synergistic environment for developing high throughput pathogenic sensors.”




Related Links:
Schott

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gas Analyzer
GE SAM
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.